News

Relapses occurred in only 4 of 14 patients treated with the combination of Metronidazole with Vancomycin.

FDA application is based on the positive data from 3 recent phase 3 clinical trials.

These findings suggest a potential in developing preventative vaccines against C. difficile infection.

Multi-center, sickle cell studies may face a host of barriers and challenges in achieving target sample sizes.

Screenings for ADHD have not improved in several years.

New data show patients hospitalized with COVID-19 far more frequently suffer from cardiometabolic disease, yet face worse outcomes with COPD.

A younger baseline age and more injections during the first year of treatment was linked to better long-term outcomes.

Venetoclax in combination with azacitidine was shown to prolong survival and increase chance of remission.

The COVID-19 pandemic has placed burdens on access to in-person health services; therefore, safe and practical allergy management / prevention processes are necessary.

New data shows that clinical isolates of C. difficile are variably affected by manuka honey in terms of growth inhibition and bactericidal activity.

Patients diagnosed with neurologic disorders post-admission were less likely to be discharged home than those with events prior to, or at the time of admission.

A large population study in Taiwan found regular use of aspirin for prevention of cardiac events increased risk for age-related macular degeneration.

The LIVMOR Halo AF Detection System has received 510(k) clearance from the US FDA and becomes the first prescriptible wearable for continuous heart monitoring in patients with atrial fibrillation.

Medications in psychiatry are often ineffective for patients.

Only 29.5% of sampled CBD users claimed any wellness benefit.

Many patients do not see meaningful improvement with the current standard treatment. New data suggest this monoclonal antibody might be a better choice.

The quadrivalent, virus-like particle influenza vaccine has potential to offer substantial protection in adults.

The longitudinal study included 209 children, one of the largest samples in the world for a study on this topic.

A higher proportion of risankizumab users achieved improved measures for symptoms, quality of life, and mental health versus comparators.

Dr. Cortese discusses how new research can drive changes to ADHD clinical trials.

The first-in-class drug in severe asthma significantly reduced the exacerbation rate by 35% compared with placebo.

The absolute SCr criterion correlated better with all-cause mortality than the relative increase in serum creatinine.

The study observed 50 women taking infliximab, adalimumab, and vedolizumab.

The drug has potential to be best-in-class treatment option for children aged 6-11 years with uncontrolled moderate-to-severe asthma.

The younger generation is able to adapt to new technology for therapy better than previous generations.

Length of stay, cost, and the mortality rate all increase among patients with chronic kidney disease compared to patients who do not suffer from CKD.

A daily drop of oxymetazoline ophthalmic could avert surgery for acquired ptosis, according to new findings.

Though atopic dermatitis is a relatively common condition, most of the existing scientific literature has ignored the majority of patients who have mild or limited disease.